ArticleGerontology2026
Sarcopenia in Older Patients with Newly Diagnosed Multiple Myeloma.
Article in Gerontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Psoas and pectoralis muscle indices and brown adipose tissue activity may be prognostic indicators in older patients with multiple myeloma.International journal of hematology · 2026Article
- Efficacy of exercise interventions in multiple myeloma: a systematic review and meta-analysis.Journal of cancer survivorship : research and practice · 2026Review
- Advances in the application of frailty scoring in the diagnosis and management of elderly patients with multiple myeloma (Review).Oncology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Introduction: Sarcopenia is an age-related condition characterised by low muscle mass and function, associated with poorer outcomes. Its prevalence and prognostic role in multiple myeloma (MM) remain unclear, as most studies only consider muscle mass defined by computed tomography (CT) scan and disregard muscle function. This study aimed to describe the prevalence of sarcopenia according to the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) definition in older patients with MM and to analyse its associations with other geriatric syndromes and survival outcomes.
methodsThis is a prospective study of patients aged ≥65 years with newly diagnosed MM who underwent a Comprehensive Geriatric Assessment (CGA), including handgrip strength and gait speed. Their initial positron emission tomography-computed tomography images were evaluated in terms of muscle mass, subcutaneous and visceral adipose tissue at the third lumbar vertebral level (L3). Medical records were reviewed in January 2025 to collect mortality and follow-up data.
resultsOf 52 patients included (55.1% women; median age 77.6 ± 5.9 years), 32 (61.5%) had probable sarcopenia (low muscle strength), and four (12.5%) had confirmed sarcopenia (low muscle strength and low muscle mass). No significant differences were found in frailty or malnutrition between sarcopenic and non-sarcopenic participants. Sarcopenic patients had significantly shorter overall survival (OS) compared with non-sarcopenic patients (43.1 vs. 18.0 months, p = 0.001), and low muscle mass was independently associated with poorer survival outcomes (hazard ratio [HR]: 46.8; 95% confidence interval [CI]: 1.9-1,146.9). In contrast, no significant differences were observed for progression-free survival (PFS), although low muscle mass remained significantly associated with an increased risk of progression (HR: 25.34; 95% CI: 1.72-374.27).
conclusionThis is the first study to include both muscle quantity (muscle mass) and function (muscle strength) as the correct approach for sarcopenia evaluation in older patients with MM. Patients with sarcopenia may have reduced OS, and low skeletal muscle mass index was also associated with shorter PFS, but further studies with larger cohorts are needed to confirm its prognostic value. </p>.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.